New combo offers hope for aggressive lymphoma in diverse patients
NCT ID NCT04981795
First seen May 07, 2026 · Last updated Jun 17, 2026 · Updated 8 times
Summary
This study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic minority patients. Researchers measured side effects, tumor shrinkage, and how long patients lived without the cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama Oncology
Birmingham, Alabama, 35211, United States
-
American Oncology Partners of Maryland PA
Bethesda, Maryland, 20817, United States
-
Clearview Cancer Institute
Huntsville, Alabama, 35805, United States
-
Duke University
Durham, North Carolina, 27705, United States
-
Froedtert & Medical College Clinics
Milwaukee, Wisconsin, 53226, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Integris Cancer Institute of Oklahoma
Oklahoma City, Oklahoma, 73142, United States
-
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096, United States
-
Leo Jenkins Cancer Center/ECU School of Medicine
Greenville, North Carolina, 27858, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
McFarland Clinic P.C.
Ames, Iowa, 50010, United States
-
Mercy Medical Center
Canton, Ohio, 44708, United States
-
Mission Cancer and Blood
Des Moines, Iowa, 50309, United States
-
Morristown Medical Center
Morristown, New Jersey, 07960-6136, United States
-
Ohio Health Marion Area Physicians
Marion, Ohio, 43302, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903-2681, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
Tri County Hematology & Oncology Associates, Inc
Massillon, Ohio, 44646, United States
-
Tulane Cancer Center
New Orleans, Louisiana, 70112, United States
-
UW Medicine
Seattle, Washington, 98109, United States
-
University of California, Irvine Medical Center
Orange, California, 92868, United States
-
University of Michigan Comprehensive Cancer Center Michigan Medicine
Ann Arbor, Michigan, 48109, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
VA Medical Center - Durham
Durham, North Carolina, 27705, United States
-
Westchester Medical Center
Hawthorne, New York, 10532, United States
-
Yakima Valley Memorial Hospital/North Star Lodge
Yakima, Washington, 98902, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.